Urinary endogenous peptides as biomarkers for prostate cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/267855 |
Resumo: | Prostate cancer (PCa) is one of the most prevalent types of cancer in men worldwide; however, the main diagnostic tests available for PCa have limitations and a biopsy is required for histopathological confirmation of the disease. Prostate specific antigen (PSA) is the main biomarker used for the early detection of PCa, but an elevated serum concentration is not cancer specific. Therefore, there is a need for the discovery of new non invasive biomarkers that can accurately diagnose PCa. The present study used trichloroacetic acid induced protein precipitation and liquid chromatography mass spectrometry to profile endogenous peptides in urine samples from patients with PCa (n=33), benign prostatic hyperplasia (n=25) and healthy individuals (n=28). Receiver operating characteristic curve analysis was performed to evaluate the diagnostic performance of urinary peptides. In addition, Proteasix tool was used for in silico prediction of protease cleavage sites. Five urinary peptides derived from uromodulin were revealed to be significantly altered between the study groups, all of which were less abundant in the PCa group. This peptide panel showed a high potential to discriminate between the study groups, resulting in area under the curve (AUC) values between 0.788 and 0.951. In addition, urinary peptides outperformed PSA in discriminating between malignant and benign prostate conditions (AUC=0.847), showing high sensitivity (81.82%) and specificity (88%). From in silico analyses, the proteases HTRA2, KLK3, KLK4, KLK14 and MMP25 were identified as potentially involved in the degradation of uromodulin peptides in the urine of patients with PCa. In conclusion, the present study allowed the identification of urinary peptides with potential for use as non invasive biomarkers in PCa diagnosis. |
id |
UFRGS-2_a2ea5c8355dd4f3a55f2a1b84f47d3b0 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/267855 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Dutra, Cristine de SouzaSchafhauser, Deborah da CruzHentz, MarianaMayer, Nicole RauppPinheiro, Raiane MedeirosBaierle, GabrielaKist, Djulia RafaellaBullé, Danielly JoaniDonaduzzi, Rodrigo CattelanBohmgahren, Marcus FalcãoZaha, ArnaldoFerreira, Henrique BunselmeyerPossuelo, Lia GonçalvesMonteiro, Karina Mariante2023-11-30T03:24:50Z20231792-1082http://hdl.handle.net/10183/267855001170381Prostate cancer (PCa) is one of the most prevalent types of cancer in men worldwide; however, the main diagnostic tests available for PCa have limitations and a biopsy is required for histopathological confirmation of the disease. Prostate specific antigen (PSA) is the main biomarker used for the early detection of PCa, but an elevated serum concentration is not cancer specific. Therefore, there is a need for the discovery of new non invasive biomarkers that can accurately diagnose PCa. The present study used trichloroacetic acid induced protein precipitation and liquid chromatography mass spectrometry to profile endogenous peptides in urine samples from patients with PCa (n=33), benign prostatic hyperplasia (n=25) and healthy individuals (n=28). Receiver operating characteristic curve analysis was performed to evaluate the diagnostic performance of urinary peptides. In addition, Proteasix tool was used for in silico prediction of protease cleavage sites. Five urinary peptides derived from uromodulin were revealed to be significantly altered between the study groups, all of which were less abundant in the PCa group. This peptide panel showed a high potential to discriminate between the study groups, resulting in area under the curve (AUC) values between 0.788 and 0.951. In addition, urinary peptides outperformed PSA in discriminating between malignant and benign prostate conditions (AUC=0.847), showing high sensitivity (81.82%) and specificity (88%). From in silico analyses, the proteases HTRA2, KLK3, KLK4, KLK14 and MMP25 were identified as potentially involved in the degradation of uromodulin peptides in the urine of patients with PCa. In conclusion, the present study allowed the identification of urinary peptides with potential for use as non invasive biomarkers in PCa diagnosis.application/pdfengOncology letters. Greece. Vol. 25, no. 4 (Apr. 2023), e173Neoplasias da próstataBiomarcadoresEndogenous peptidesMass spectrometryUrinary endogenous peptides as biomarkers for prostate cancerEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001170381.pdf.txt001170381.pdf.txtExtracted Texttext/plain46765http://www.lume.ufrgs.br/bitstream/10183/267855/2/001170381.pdf.txt1ed7158a14cae2ffafd1c1688e3e208fMD52ORIGINAL001170381.pdfTexto completo (inglês)application/pdf824427http://www.lume.ufrgs.br/bitstream/10183/267855/1/001170381.pdfb7461de7a9a5f97728165f8b9d07d668MD5110183/2678552023-12-06 04:25:41.601662oai:www.lume.ufrgs.br:10183/267855Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-12-06T06:25:41Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Urinary endogenous peptides as biomarkers for prostate cancer |
title |
Urinary endogenous peptides as biomarkers for prostate cancer |
spellingShingle |
Urinary endogenous peptides as biomarkers for prostate cancer Dutra, Cristine de Souza Neoplasias da próstata Biomarcadores Endogenous peptides Mass spectrometry |
title_short |
Urinary endogenous peptides as biomarkers for prostate cancer |
title_full |
Urinary endogenous peptides as biomarkers for prostate cancer |
title_fullStr |
Urinary endogenous peptides as biomarkers for prostate cancer |
title_full_unstemmed |
Urinary endogenous peptides as biomarkers for prostate cancer |
title_sort |
Urinary endogenous peptides as biomarkers for prostate cancer |
author |
Dutra, Cristine de Souza |
author_facet |
Dutra, Cristine de Souza Schafhauser, Deborah da Cruz Hentz, Mariana Mayer, Nicole Raupp Pinheiro, Raiane Medeiros Baierle, Gabriela Kist, Djulia Rafaella Bullé, Danielly Joani Donaduzzi, Rodrigo Cattelan Bohmgahren, Marcus Falcão Zaha, Arnaldo Ferreira, Henrique Bunselmeyer Possuelo, Lia Gonçalves Monteiro, Karina Mariante |
author_role |
author |
author2 |
Schafhauser, Deborah da Cruz Hentz, Mariana Mayer, Nicole Raupp Pinheiro, Raiane Medeiros Baierle, Gabriela Kist, Djulia Rafaella Bullé, Danielly Joani Donaduzzi, Rodrigo Cattelan Bohmgahren, Marcus Falcão Zaha, Arnaldo Ferreira, Henrique Bunselmeyer Possuelo, Lia Gonçalves Monteiro, Karina Mariante |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Dutra, Cristine de Souza Schafhauser, Deborah da Cruz Hentz, Mariana Mayer, Nicole Raupp Pinheiro, Raiane Medeiros Baierle, Gabriela Kist, Djulia Rafaella Bullé, Danielly Joani Donaduzzi, Rodrigo Cattelan Bohmgahren, Marcus Falcão Zaha, Arnaldo Ferreira, Henrique Bunselmeyer Possuelo, Lia Gonçalves Monteiro, Karina Mariante |
dc.subject.por.fl_str_mv |
Neoplasias da próstata Biomarcadores |
topic |
Neoplasias da próstata Biomarcadores Endogenous peptides Mass spectrometry |
dc.subject.eng.fl_str_mv |
Endogenous peptides Mass spectrometry |
description |
Prostate cancer (PCa) is one of the most prevalent types of cancer in men worldwide; however, the main diagnostic tests available for PCa have limitations and a biopsy is required for histopathological confirmation of the disease. Prostate specific antigen (PSA) is the main biomarker used for the early detection of PCa, but an elevated serum concentration is not cancer specific. Therefore, there is a need for the discovery of new non invasive biomarkers that can accurately diagnose PCa. The present study used trichloroacetic acid induced protein precipitation and liquid chromatography mass spectrometry to profile endogenous peptides in urine samples from patients with PCa (n=33), benign prostatic hyperplasia (n=25) and healthy individuals (n=28). Receiver operating characteristic curve analysis was performed to evaluate the diagnostic performance of urinary peptides. In addition, Proteasix tool was used for in silico prediction of protease cleavage sites. Five urinary peptides derived from uromodulin were revealed to be significantly altered between the study groups, all of which were less abundant in the PCa group. This peptide panel showed a high potential to discriminate between the study groups, resulting in area under the curve (AUC) values between 0.788 and 0.951. In addition, urinary peptides outperformed PSA in discriminating between malignant and benign prostate conditions (AUC=0.847), showing high sensitivity (81.82%) and specificity (88%). From in silico analyses, the proteases HTRA2, KLK3, KLK4, KLK14 and MMP25 were identified as potentially involved in the degradation of uromodulin peptides in the urine of patients with PCa. In conclusion, the present study allowed the identification of urinary peptides with potential for use as non invasive biomarkers in PCa diagnosis. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-11-30T03:24:50Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/267855 |
dc.identifier.issn.pt_BR.fl_str_mv |
1792-1082 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001170381 |
identifier_str_mv |
1792-1082 001170381 |
url |
http://hdl.handle.net/10183/267855 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Oncology letters. Greece. Vol. 25, no. 4 (Apr. 2023), e173 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/267855/2/001170381.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/267855/1/001170381.pdf |
bitstream.checksum.fl_str_mv |
1ed7158a14cae2ffafd1c1688e3e208f b7461de7a9a5f97728165f8b9d07d668 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1798487581077274624 |